![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nexvet Biopharma Plc - Ordinary Shares | NASDAQ:NVET | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.72 | 6.00 | 7.90 | 0 | 01:00:00 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
Akubra Investors, LLC |
2. Issuer Name
and
Ticker or Trading Symbol
Nexvet Biopharma plc [ NVET ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __ X __ 10% Owner _____ Officer (give title below) __ X __ Other (specify below) Member of Group Owning 10% |
C/O FARALLON CAPITAL MANAGEMENT, L.L.C., ONE MARITIME PLAZA, SUITE 2100 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
SAN FRANCISCO, CA 94111 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Ordinary Shares | 2/10/2015 | C | 566664 | A | (1) | 566664 (4) | D (2) (3) (5) | |||
Ordinary Shares | 2/10/2015 | A | 220371 | A | $10.00 | 787035 | D (2) (3) (5) | |||
Ordinary Shares | 2/10/2015 | C | 611124 | A | (1) | 611124 (4) | D (2) (3) (6) | |||
Ordinary Shares | 2/10/2015 | A | 237659 | A | $10.00 | 848783 | D (2) (3) (6) | |||
Ordinary Shares | 2/10/2015 | C | 622208 | A | (1) | 622208 (4) | D (2) (3) (7) | |||
Ordinary Shares | 2/10/2015 | A | 241970 | A | $10.00 | 864178 | D (2) (3) (7) | |||
Ordinary Shares | 2/10/2015 | C | 82912 | A | (1) | 82912 (4) | I | See Footnotes (2) (3) (5) (9) (10) | ||
Ordinary Shares | 2/10/2015 | A | 32244 | A | $10.00 | 115156 | I | See Footnotes (2) (3) (5) (9) (10) | ||
Ordinary Shares | 2/10/2015 | C | 169530 | A | (1) | 169530 (4) | I | See Footnotes (2) (3) (6) (11) | ||
Ordinary Shares | 2/10/2015 | A | 65928 | A | $10.00 | 235458 | I | See Footnotes (2) (3) (6) (11) | ||
Ordinary Shares | 2/10/2015 | C | 142424 | A | (1) | 142424 (4) | I | See Footnotes (2) (3) (7) (12) | ||
Ordinary Shares | 2/10/2015 | A | 55387 | A | $10.00 | 197811 | I | See Footnotes (2) (3) (7) (12) | ||
Ordinary Shares | 2/10/2015 | C | 1405130 | A | (1) | 1405130 (4) | I | See Footnotes (2) (3) (13) | ||
Ordinary Shares | 2/10/2015 | A | 546441 | A | $10.00 | 1951571 | I | See Footnotes (2) (3) (13) | ||
Ordinary Shares | 2/10/2015 | C | 1799996 | A | (1) | 1799996 (4) | I | See Footnotes (2) (3) (8) (14) (15) | ||
Ordinary Shares | 2/10/2015 | A | 700000 | A | (1) | 2499996 | I | See Footnotes (2) (3) (8) (14) (15) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Series B Preference Shares | (1) | 2/10/2015 | C | 566664 | (1) | (1) | Ordinary Shares | 566664 | $0 | 0 | D (2) (3) (5) | ||||
Series B Preference Shares | (1) | 2/10/2015 | C | 611124 | (1) | (1) | Ordinary Shares | 611124 | $0 | 0 | D (2) (3) (6) | ||||
Series B Preference Shares | (1) | 2/10/2015 | C | 622208 | (1) | (1) | Ordinary Shares | 622208 | $0 | 0 | D (2) (3) (7) | ||||
Series B Preference Shares | (1) | 2/10/2015 | C | 82912 | (1) | (1) | Ordinary Shares | 82912 | $0 | 0 | I | See Footnotes (5) (9) (10) | |||
Series B Preference Shares | (1) | 2/10/2015 | C | 169530 | (1) | (1) | Ordinary Shares | 169530 | $0 | 0 | I | See Footnotes (6) (11) | |||
Series B Preference Shares | (1) | 2/10/2015 | C | 142424 | (1) | (1) | Ordinary Shares | 142424 | $0 | 0 | I | See Footnotes (7) (12) | |||
Series B Preference Shares | (1) | 2/10/2015 | C | 1405130 | (1) | (1) | Ordinary Shares | 1405130 | $0 | 0 | I | See Footnotes (13) | |||
Series B Preference Shares | (1) | 2/10/2015 | C | 1799996 | (1) | (1) | Ordinary Shares | 1799996 | $0 | 0 | I | See Footnotes (8) (14) (15) |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Akubra Investors, LLC
C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO, CA 94111 |
|
X |
|
Member of Group Owning 10% | |
Bushranger Funding, LLC
C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO, CA 94111 |
|
X |
|
Member of Group Owning 10% | |
Farallon AA G.P., L.L.C.
C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO, CA 94111 |
|
X |
|
Member of Group Owning 10% | |
Farallon Partners GP VI, L.L.C.
C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO, CA 94111 |
|
X |
|
Member of Group Owning 10% | |
NGP, L.L.C.
C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO, CA 94111 |
|
X |
|
Member of Group Owning 10% | |
Ute Holdings, LLC
C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO, CA 94111 |
|
X |
|
Member of Group Owning 10% | |
Warren John R.
C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO, CA 94111 |
|
X |
|
Member of Group Owning 10% | |
WEHRLY MARK C
C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO, CA 94111 |
|
X |
|
Member of Group Owning 10% |
Signatures
|
||
/s/ Monica R. Landry, as attorney-in-fact and/or authorized signer for Akubra Investors, LLC | 2/11/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Monica R. Landry, as attorney-in-fact and/or authorized signer for Bushranger Funding, LLC | 2/11/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Monica R. Landry, as attorney-in-fact and/or authorized signer for Farallon AA GP, L.L.C. | 2/11/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Monica R. Landry, as attorney-in-fact and/or authorized signer for Farallon Partners GP VI, L.L.C. | 2/11/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Monica R. Landry, as attorney-in-fact and/or authorized signer for NGP, L.L.C. | 2/11/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Monica R. Landry, as attorney-in-fact and/or authorized signer for Ute Holdings, LLC | 2/11/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Monica R. Landry, as attorney-in-fact and/or authorized signer for John R. Warren | 2/11/2015 | |
** Signature of Reporting Person |
Date
|
|
/s/ Monica R. Landry, as attorney-in-fact and/or authorized signer for Mark C. Wehrly | 2/11/2015 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year NEXVET BIOPHARMA PLC Chart |
1 Month NEXVET BIOPHARMA PLC Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions